Innovative Patient Care
Janssen comprises companies with nearly 40,000 employees in more than 150 countries around the world. We work within and beyond our communities, globally, to bring innovative treatments for serious unmet medical needs. We make extraordinary efforts to help people enjoy ordinary moments.
Today’s medical challenges are far more complex than ever before. Yet it’s not just about finding new treatments. We look at these medical challenges in a broader context. We go beyond the medicine – ensuring people have the information, education and support to access the treatments they need and use them correctly for the best possible results. Helping people live full and happy lives inspires us. And promising new science and technology spur us on.
It all comes back to our commitment to collaboration, in research and education, all the way to patient access. We won’t stop until new ideas turn into medical solutions for patients in need.
With our unique model of innovation, Janssen has built an industry-leading pipeline. Worldwide, the Janssen pharmaceutical companies of Johnson & Johnson have had 20 consecutive quarters of operational sales growth, as reported on April 14, 2015.
Some of Janssen’s partnerships and innovations that are helping transform medicine and improve patient outcomes include:
Canadian Cancer Clinical Trials Network (3CTN), a pan-Canadian initiative to improve the efficiency and quality of academic clinical trials in Canada.
CQDM, a pharma-based consortium active in pre-competitive research whose mission is to fund the development of innovative tools and technologies to accelerate drug discovery.
MaRS Innovation, the commercialization agent for Ontario’s 15 leading academic institutions, to advance three technologies focused on cardiac, diabetes and depression, respectively.
Ontario Institute for Cancer Research (OICR), an innovative cancer research and development institute dedicated to prevention, early detection, diagnosis and treatment of cancer.
JLABS @ Toronto, a life science incubator, and a collaboration between Johnson & Johnson Innovation LLC, the University of Toronto, MaRS Discovery District, Janssen Inc., MaRS Innovation and the Government of Ontario.
MaRS (where JLABS @ Toronto is located) recently announced that it successfully secured private sector financing allowing it to repay the loan it received from the Government of Ontario. Click here to read our letter of congratulations to the Honourable Kathleen Wynne. Click here to read our letter of congratulations to Dr. Ilse Treurnicht, CEO, MaRS Discovery District.
Johnson & Johnson Diabetes Research Fund partnering with the Government of Alberta and the Alberta Diabetes Foundation, to support research in either Type I or Type II diabetes with a focus on novel, discovery research with a high potential for commercialization.